U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Dana T, Blazina I, et al. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Nov. (Evidence Syntheses, No. 139.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Statin Use for the Prevention of Cardiovascular Disease in Adults

Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

Show details

References

1.
Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 Oct 6;151(7):496–507. [PubMed: 19805772]
2.
Pignone MP, Phillips CJ, Atkins D, et al. Screening and treating adults for lipid disorders. Am J Prev Med. 2001 Apr;20(3 Suppl):77–89. [PubMed: 11306236]
3.
Pignone MP, Phillips CJ, Lannon CM, et al. Screening for Lipid Disorders. Rockville (MD): Agency for Healthcare Research and Quality; 2001. AHRQ Publication No. 01-S004. http://www​.ahrq.gov/downloads​/pub/prevent/pdfser/lipidser​.pdf. [PubMed: 20722136]
4.
U.S. Preventive Services Task Force. Screening for Lipid Disorders in Adults: Recomendation Statement Agency for Healthcare Research and Quality. Rockville (MD): 2008. [February 19, 2014]. AHRQ Publication No. 08-05114-EF-2. http://www​.uspreventiveservicestaskforce​.org/uspstf08/lipid/lipidrs.htm.
5.
Chou R, Dana T, Blazina I, et al. Screening for Lipid Disorders in Younger Adults: Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation Agency for Healthcare Research & Quality. Rockville, MD: in press.
6.
Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Affairs. 2007 Jan-Feb;26(1):38–48. [PubMed: 17211012]
7.
Hoyert DL. 75 years of mortality in the United States, 1935-2010. NCHS Data Brief. 2012 Mar;(88):1–8. [PubMed: 22617094]
8.
Minino AM. Death in the United States, 2011. NCHS Data Brief. 2013 Mar;(115):1–8. [PubMed: 23742756]
9.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. [PMC free article: PMC5408511] [PubMed: 23239837]
10.
Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1–65. [PubMed: 24984457]
11.
Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012 Jan 3;125(1):e2–e220. [PMC free article: PMC4440543] [PubMed: 22179539] [CrossRef]
12.
Centers for Disease Control and Prevention. Prevalence of coronary heart disease--United States, 2006-2010. Morb Mortal Wkly Rep. 2011 Oct 14;60(40):1377–81. [PubMed: 21993341]
13.
Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar;83(3):361–6. [PMC free article: PMC1729334] [PubMed: 10677422]
14.
Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383–90. [PubMed: 3946178]
15.
Lecerf JM, de Lorgeril M. Dietary cholesterol: from physiology to cardiovascular risk. Br J Nutr. 2011 Jul;106(1):6–14. [PubMed: 21385506] [CrossRef]
16.
National Institutes of Health. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Cholesterol Education Program. 2002. [February 19, 2014]. NIH Publication No. 02-5215. http://www​.nhlbi.nih​.gov/guidelines/cholesterol/atp3_rpt.htm. [PubMed: 12485966]
17.
Sheifer SE, Gersh BJ, Yanez ND, et al. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol. 2000;35(1):119–26. [PubMed: 10636269]
18.
Sigurdsson E, Thorgeirsson G, Sigvaldason H, et al. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris: the Reykjavik Study. Ann Intern Med. 1995;122(2):96–102. [PubMed: 7993002]
19.
Welsh JA, Sharma A, Abramson JL, et al. Caloric sweetener consumption and dyslipidemia among us adults. JAMA. 2010;303(15):1490–7. [PMC free article: PMC3045262] [PubMed: 20407058] [CrossRef]
20.
Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325–30. [PubMed: 22836069] [CrossRef]
21.
Centers for Disease Control and Prevention. Cholesterol: Risk Factors. 2010. [February 19, 2014]. http://www​.cdc.gov/cholesterol​/risk_factors.htm.
22.
Coffey S. Dyslipidemia. U.S. Department of Health and Human Services, Health Resources and Services Administration. 2011. [February 19, 2014]. http://hab​.hrsa.gov/deliverhivaidscare​/clinicalguide11​/cg-602_dyslipidemia.html.
23.
Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45(4):293–304. [PubMed: 12638093] [CrossRef]
24.
Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry. 2004;65(4):547. [PubMed: 15119919]
25.
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–45. [PubMed: 21487090]
26.
Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. [PMC free article: PMC3284229] [PubMed: 19903920]
27.
Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009 Jan 27;53(4):316–22. [PubMed: 19161879] [CrossRef]
28.
Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011;58(5):457–63. [PubMed: 21777740]
29.
Arsenault BJ, Mora S, Nestel PJ, et al. Clinician's Corner. Association of LDL cholesterol, non – HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events. JAMA. 2012;307(12) [PubMed: 22453571]
30.
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25 Pt B):2889–934. [PubMed: 24239923]
31.
Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–97. [PubMed: 17159064]
32.
Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8):S69–S76. [PubMed: 16581332]
33.
Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005 Jun 14;111(23):3051–7. [PubMed: 15911706]
34.
Richardson K, Schoen M, French B, et al. Statins and cognitive function: A systematic review. Ann Intern Med. 2013;159(10):688–97. [PubMed: 24247674]
35.
Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80. [PubMed: 16391219]
36.
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762–5. [PubMed: 24268611]
37.
Lloyd-Jones DM, Goff D, Stone NJ. Statins, risk assessment, and the new American prevention guidelines. Lancet. 2013;383(9917):600–2. [PubMed: 24315619] [CrossRef]
38.
Karmali KN, Goff DC Jr., Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Sep 9;64(10):959–68. [PubMed: 25190228] [CrossRef]
39.
Miedema MD, Lopez FL, Blaha MJ, et al. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan;175(1):138–40. [PMC free article: PMC4652650] [PubMed: 25401375] [CrossRef]
40.
Pursnani A, Massaro JM, D'Agostino RB Sr., et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015 Jul 14;314(2):134–41. [PMC free article: PMC4754085] [PubMed: 26172893] [CrossRef]
41.
Lopez-Jimenez F, Simha V, Thomas RJ, et al. A summary and critical assessment of the 2013 AA/AHA guideline on the treatment of the blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. Mayo Clin Proc. 2014;89(9):1257–78. [PubMed: 25131697]
42.
National Institute for Health and Care Excellence (NICE). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014. [August 9, 2016]. http://www​.nice.org.uk/guidance/cg181. [PubMed: 25340243]
43.
Board J. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014 April 1;100(Suppl 2):ii1–ii67. 2014. [PubMed: 24667225] [CrossRef]
44.
The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and the European Atherosclerosis Society. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818. [PubMed: 21712404]
45.
Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67. [PubMed: 23351925]
46.
International Atherosclerosis Society. Global recommendations for the management of dyslipidemia. 2014. [October 20, 2014]. http://www​.athero.org​/download/IASPPGuidelines_FullReport_2​.pdf.
47.
Department of Veterans Affairs. VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2014. [July 21, 2016]. http://www​.healthquality​.va.gov/guidelines​/CD/lipids/VADoDDyslipidemiaCPG2014​.pdf.
48.
Cholesterol Treatment Trialists Collaborators. Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581–90. [PMC free article: PMC3437972] [PubMed: 22607822] [CrossRef]
49.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
50.
Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014 Feb 18;160(4):267–70. [PubMed: 24727843] [CrossRef]
51.
Sterne JA, Sutton AJ, Ioannidis J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. [PubMed: 21784880]
52.
Furberg CD, Adams HP Jr., Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994 Oct;90(4):1679–87. [PubMed: 7734010]
53.
ACAPS Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). Control Clin Trials. 1992;13:293–314. [PubMed: 1330434]
54.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–22. [PubMed: 9613910]
55.
Downs JR, Beere PA, Whitney E, et al. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 1997 Aug 1;80(3):287–93. [PubMed: 9264420]
56.
Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001 May 1;87(9):1074–9. [PubMed: 11348605]
57.
Gotto AM Jr., Whitney E, Stein EA, et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur Heart J. 2000 Oct;21(19):1627–33. [PubMed: 10988016]
58.
Gotto AM Jr., Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000 Feb 8;101(5):477–84. [PubMed: 10662743]
59.
Gotto AM Jr. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Atheroscler Suppl. 2007 Aug;8(2):3–8. [PubMed: 17588826]
60.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149–58. [PubMed: 12686036]
61.
Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001 Jun;19(6):1139–47. [PubMed: 11403364]
62.
Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005 May;28(5):1151–7. [PubMed: 15855581]
63.
Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006 Jul;29(7):1478–85. [PubMed: 16801565]
64.
Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010 Jan 19;121(2):306–14. [PubMed: 20048204] [CrossRef]
65.
Beishuizen ED, van de Ree MA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2004 Dec;27(12):2887–92. [PubMed: 15562202]
66.
Bone HG, Kiel DP, Lindsay RS, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007 Dec;92(12):4671–7. [PubMed: 17726081] [CrossRef]
67.
Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996 Dec;101(6):627–34. [PubMed: 9003110]
68.
Sirtori CR, Bianchi G, Bond MG, et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. Int J Card Imaging. 1995;11(Suppl 2):119–24.
69.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685–96. [PubMed: 15325833]
70.
Colhoun HM, Thomason MJ, Mackness MI, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Med. 2002 Mar;19(3):201–11. [PubMed: 11918622]
71.
Neil HAW, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006 Nov;29(11):2378–84. [PubMed: 17065671]
72.
Heljić B, Velija-Asimi Z, Kulic M. The statins in prevention of coronary heart diseases in type 2 diabetics. Bosn J Basic Med Sci. 2009 Feb;9(1):71–6. [PMC free article: PMC5645552] [PubMed: 19284399]
73.
Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 2005 Feb;178(2):387–97. [PubMed: 15694949] [CrossRef]
74.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195–207. [PubMed: 18997196] [CrossRef]
75.
Ridker PM, Fonseca FAH, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007 Dec 1;100(11):1659–64. [PubMed: 18036365]
76.
Ridker PM., Group JS. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003 Nov 11;108(19):2292–7. [PubMed: 14609996]
77.
Albert MA, Glynn RJ, Fonseca FAH, et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. 2011 Jul;162(1):106–14.e2. [PubMed: 21742096] [CrossRef]
78.
Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010 Apr 20;152(8):488–96. 2010. [PMC free article: PMC2946369] [PubMed: 20404379] [CrossRef]
79.
Ridker PM, Macfadyen JG, Nordestgaard BG, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for “intermediate risk” Circulation. 2010 Sep;3(5):447–52. [PubMed: 20736443] [CrossRef]
80.
Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk > 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2011 Jan;32(1):75–83. [PMC free article: PMC3013199] [PubMed: 20971747] [CrossRef]
81.
Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 9;121(9):1069–77. [PMC free article: PMC4439924] [PubMed: 20176986] [CrossRef]
82.
Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995 Oct 1;92(7):1758–64. [PubMed: 7671358]
83.
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006 Sep 30;368(9542):1155–63. [PubMed: 17011942]
84.
Tajima N, Kurata H, Nakaya N, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis. 2008 Aug;199(2):455–62. [PubMed: 18635188] [CrossRef]
85.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J. 2004 Sep;68(9):860–7. [PubMed: 15329509]
86.
Uchiyama S, Nakaya N, Mizuno K, et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci. 2009 Sep 15;284(1-2):72–6. [PubMed: 19423132] [CrossRef]
87.
Kushiro T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009 Feb;53(2):135–41. [PubMed: 19104004] [CrossRef]
88.
Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008 Jan 29;117(4):494–502. [PubMed: 18172039] [CrossRef]
89.
Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011 Sep 1;28(9):681–92. [PubMed: 21815708] [CrossRef]
90.
Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009 Oct;206(2):512–7. [PubMed: 19423108] [CrossRef]
91.
Nishiwaki M, Ikewaki K, Ayaori M, et al. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study. J Cardiol. 2013 Mar;61(3):196–200. [PubMed: 23265677] [CrossRef]
92.
Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004 Dec 1;117(11):823–9. [PubMed: 15589485] [CrossRef]
93.
Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344–53. [PubMed: 17384434] [CrossRef]
94.
Crouse J, Grobbee DE, O'Leary DH, et al. Measuring effect on intima medial thickness: a evaluation of rosuvastatin in subclinical artherosclerosis - the rationale and methodology of the METEOR Study. Cardiovasc Drugs Ther. 2004;18:231–8. [PubMed: 15229392]
95.
Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004 Nov 2;110(18):2809–16. [PubMed: 15492322]
96.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–7. [PubMed: 7566020]
97.
Clearfield M, Whitney EJ, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. J Cardiovasc Risk. 2000 Apr;7(2):125–33. [PubMed: 10879416]
98.
Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001 Dec;10(10):971–81. [PubMed: 11788107]
99.
Kendrick J, Shlipak MG, Targher G, et al. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010 Jan;55(1):42–9. [PMC free article: PMC2803327] [PubMed: 19932541] [CrossRef]
100.
Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959–65. [PubMed: 11430324]
101.
Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 Jan 23;103(3):357–62. [PubMed: 11157685]
102.
Newman CB, Szarek M, Colhoun HM, et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res. 2008 Sep;5(3):177–83. [PubMed: 18777490] [CrossRef]
103.
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021–31. [PubMed: 27040132] [CrossRef]
104.
Lonn E, Bosch J, Pogue J, et al. Novel approaches in primary cardiovascular disease prevention: The HOPE-3 trial rationale, design, and participants' baseline characteristics. Can J Cardiol. 2016 Mar;32(3):311–8. [PubMed: 26481083] [CrossRef]
105.
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1 CD004816. DOI: 10.1002/14651858.CD004816.pub5. [PMC free article: PMC6481400] [PubMed: 23440795] [CrossRef]
106.
Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995 Sep 28;76(9):113C–7C. [PubMed: 7572679]
107.
U.S. Food & Drug Administration Division of Metabolism and Endocrinology Products (DMEP). Memorandum: 15 December 2008, Advisory Committee meeting for rosuvastatin Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. 2009. [August 9, 2016]. http://www​.fda.gov/downloads​/AdvisoryCommittees​/CommitteesMeetingMaterials​/Drugs​/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831​.pdf.
108.
McGorrian C, Yusuf S, Islam S, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J. 2011 Mar;32(5):581–9. [PubMed: 21177699] [CrossRef]
109.
Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11;380(9841):565–71. [PMC free article: PMC3774022] [PubMed: 22883507] [CrossRef]
110.
Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004 Sep;58(3):303–9. [PMC free article: PMC1884569] [PubMed: 15327590]
111.
Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012 Jan 23;172(2):144–52. [PubMed: 22231607] [CrossRef]
112.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. [PubMed: 20167359] [CrossRef]
113.
Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935–59. [PMC free article: PMC4700825] [PubMed: 24239921] [CrossRef]
114.
Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol. 2003 Sep;56(9):880–90. [PubMed: 14505774]
115.
National Cholesterol Education Program Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143–421. [PubMed: 12485966]
116.
D'Agostino RB Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743–53. [PubMed: 18212285] [CrossRef]
117.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002 Jan 22;105(3):310–5. [PubMed: 11804985]
118.
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008 Jun 28;336(7659):1475–82. [PMC free article: PMC2440904] [PubMed: 18573856] [CrossRef]
119.
Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007 Feb 14;297(6):611–9. [PubMed: 17299196] [CrossRef]
120.
Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008 Nov 25;118(22):2243–51. 4p following 51. [PMC free article: PMC2752381] [PubMed: 18997194] [CrossRef]
121.
Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987–1003. [PubMed: 12788299]
122.
Matheny M, McPheeters M, Glasser A, et al. Systematic Review of Cardiovascular Disease Risk Assessment Tools Agency for Healthcare Research & Quality. Rockville, MD: 2011. [August 9, 2016]. http://www​.ncbi.nlm.nih​.gov/books/NBK56166/ [PubMed: 21796824]
123.
U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Events: Final Research Plan. 2016. [August 9, 2016]. AHRQ Publication No. 13-05195-EF-5. http://www​.uspreventiveservicestaskforce​.org/Page/Document/final-research-plan-aspirin-to-prevent-cardiovascular-diseas​/aspirin-to-prevent-cardiovascular-disease-and-cancer.
124.
D'Agostino RB S, Grundy S, Sullivan LM, et al. Validation of the framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7. [PubMed: 11448281] [CrossRef]
125.
Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318. [PubMed: 22628003] [CrossRef]
126.
Preiss D, Kristensen SL. The new pooled cohort equations risk calculator. Can J Cardiol. 2015 May;31(5):613–9. [PubMed: 25843167] [CrossRef]
127.
Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406–15. [PMC free article: PMC4189930] [PubMed: 24682252] [CrossRef]
128.
DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–75. [PMC free article: PMC4414494] [PubMed: 25686167]
129.
Cook NR, Ridker PM. Further insight into the Cardiovascular Risk Calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014. Published online October 6, 2014. [PMC free article: PMC4394380] [PubMed: 25285455] [CrossRef]
130.
Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016 May 10;67(18):2118–30. [PMC free article: PMC5097466] [PubMed: 27151343] [CrossRef]
131.
Kreger BE, Odell PM, D'Agostino RB, et al. Long-term intraindividual cholesterol variability: natural course and adverse impact on morbidity and mortality--the Framingham Study. Am Heart J. 1994 Jun;127(6):1607–14. [PubMed: 8197990]
132.
Bakx JC, van den Hoogen HJ, Deurenberg P, et al. Changes in serum total cholesterol levels over 18 years in a cohort of men and women: The Nijmegen Cohort Study. Prev Med. 2000 Feb;30(2):138–45. [PubMed: 10656841]
133.
Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997 Jul 1;96(1):37–43. [PubMed: 9236414]
134.
Glasziou PP, Irwig L, Heritier S, et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med. 2008 May 6;148(9):656–61. [PubMed: 18458278]
135.
Wilsgaard T, Jacobsen BK, Schirmer H, et al. Tracking of cardiovascular risk factors: the Tromso study, 1979-1995. Am J Epidemiol. 2001 Sep 1;154(5):418–26. [PubMed: 11532783]
136.
Ulmer H, Kelleher C, Diem G, et al. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: the Vorarlberg Health Monitoring & Promotion Programme. Eur Heart J. 2003 Jun;24(11):1004–13. [PubMed: 12788300]
137.
Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010 Jun 28;170(12):1024–31. [PubMed: 20585067] [CrossRef]
138.
Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ. 2011;183(16):E1189–E202. [PMC free article: PMC3216447] [PubMed: 21989464]
139.
Stone NJ, Robinson J, Lichtenstein AH, et al. Evidence Report: Managing high blood cholesterol in adults—systematic evidence review from the cholesterol expert panel, 2013 US Department of Health and Human Services. 2013. [October 9, 2014]. http://www​.nhlbi.nih​.gov/sites/www.nhlbi​.nih.gov/files/cholesterol-in-adults.pdf.
140.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002 Dec 18;288(23):2998–3007. [PubMed: 12479764]
141.
Hennekens CH. The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real? Curr Atheroscler Rep. 2004 Jan;6(1):9–11. [PubMed: 14662102]
142.
Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–54.e1. [PubMed: 17398372] [CrossRef]
143.
Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13(2):84–90. [PubMed: 20377811] [CrossRef]
144.
Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010 Jun 28;170(12):1073–7. [PubMed: 20585074] [CrossRef]
145.
Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007 Aug 10;25(23):3462–8. [PubMed: 17687150]
146.
Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid in individual patient choice. Eur J Prev Cardiolog. 2014;21(4):464–74. [PubMed: 24623264]
147.
Macedo AF, Taylor F, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12(51) [PMC free article: PMC3998050] [PubMed: 24655568]
148.
Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96–103. [PMC free article: PMC4450764] [PubMed: 23183941] [CrossRef]
149.
Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90. [PubMed: 27039291]
150.
Kostis JB, Dobrzynski JM. Prevention of cataracts by statins: a meta-analysis. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):191–200. [PubMed: 24311734] [CrossRef]
151.
Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011 Dec;22(6):460–6. [PubMed: 21897230] [CrossRef]
152.
Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009 Oct;32(10):1924–9. [PMC free article: PMC2752935] [PubMed: 19794004] [CrossRef]
153.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556–64. [PubMed: 21693744] [CrossRef]
154.
Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244. [PMC free article: PMC4038449] [PubMed: 24874977] [CrossRef]
155.
Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014 Feb 6;94(2):198–208. [Erratum appears in Am J Hum Genet. 2014 Feb 6;94(2):312] [PMC free article: PMC3928659] [PubMed: 24462370] [CrossRef]
156.
Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2014 [PMC free article: PMC4322187] [PubMed: 25262344]
157.
Strom BL, Schinnar R, Karlawish J, et al. Statin therapy and risk of acute memory impairment. JAMA Intern Med. 2015 Aug;175(8):1399–405. [PMC free article: PMC5487843] [PubMed: 26054031] [CrossRef]
158.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623–30. [PubMed: 12457784]
159.
Song F, Xiong T, Parekh-Bhurke S, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ. 2011;343:d4909. [PMC free article: PMC3156578] [PubMed: 21846695] [CrossRef]
160.
Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28(02):138–44. [PubMed: 22559755]
161.
Pham B, Klassen TP, Lawson ML, et al. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol. 2005;58(8):769–76.e2. [PubMed: 16086467]
162.
Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. [PubMed: 23235689] [CrossRef]
163.
Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008 Mar;29(2):109–13. [PubMed: 17919992]
164.
Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol. 2008 Dec;66(6):767–73. [PMC free article: PMC2675760] [PubMed: 18754841] [CrossRef]
165.
Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a netword meta-analysis of LDL cholesterol redution in randomized trials of statins. BMJ. 2014;349:g5741. [PMC free article: PMC4184241] [PubMed: 25281681]
166.
Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014 Apr 9;311(14):1416–23. [PubMed: 24681960] [CrossRef]
167.
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500–9. [PubMed: 25773607] [CrossRef]
168.
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489–99. [PubMed: 25773378] [CrossRef]
169.
Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA. 2014 Sep 17;312(11):1136–44. [PubMed: 25226479] [CrossRef]
170.
Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriat Cardio. 2003 Jul-Aug;12(4):225–31. [PubMed: 12888702]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...